A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2011
At a glance
- Drugs Alisertib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Millennium
- 17 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 17 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.